mass spectrometry is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
economic development assistance should be provided primarily through loans, continuingly, and related closely to technical assistance. ... I recommend a clear separation of military and defense support assistance on the one hand, from economic development assistance on the other. ... I recommend that long[-]term development assistance be provided from a Development Loan Fund. ... Such loans should not compete with or replace such existing sources of credit [to] private investors, the International Bank [the World Bank], or the Export-Import Bank. ... I believe the Fund should be established and administered in the International Cooperation Administration. ... The technical cooperation program is one of the most valuable elements of our entire mutual security effort. It also should be continued on a long-term basis and must be closely related to the work of the Fund." As a result, the Development Loan Fund was established in August 1957. The DLF largely financed infrastructure (such as railroads, highways, and power plants), factories, and agriculture with loans whose terms were relatively "soft" in the sense of charging interest rates lower than commercial levels and being repayable in local currency rather than U.S. dollars. Some projects were financed by a combination of a DLF soft loan and a harder World Bank loan. Operationally, the DLF became administratively self-contained by 1959 after contracting for administrative support from ICA for its first two years.
== Bioequivalence == In determining bioequivalence between two products such as a commercially available Branded product and a potential to-be-marketed Generic product, pharmacokinetic studies are conducted whereby each of the preparations are administered in a cross-over study (sometimes parallel study, when a cross-over study is not feasible) to volunteer subjects, generally healthy individuals but occasionally in patients. Serum/plasma samples are obtained at prescribed times and assayed for parent drug (or occasionally metabolite) concentration. Occasionally, blood concentration levels are neither feasible or possible to compare the two products (e.g. inhaled corticosteroids), then pharmacodynamic endpoints rather than pharmacokinetic endpoints (see below) are used for comparison. For a pharmacokinetic comparison, the plasma concentration data are used to assess key pharmacokinetic parameters such as area under the curve (AUC), peak concentration (Cmax), time to peak concentration (tmax), and absorption lag time (tlag). Testing should be conducted at several different doses, especially when the drug displays non-linear pharmacokinetics. In addition to data from bioequivalence studies, other data may need to be submitted to meet regulatory requirements for bioequivalence. Such evidence may include:
==== South Africa ==== There are two major brands of cider produced in South Africa, Hunters and Savanna. They are produced and distributed through Heineken, which acquired Distell in April 2023. Hunters Gold was first introduced in South Africa in 1988 as an alternative to beer. The Hunters range includes Hunters Dry, Hunters Gold, Hunters Export and Hunters Edge launched in April 2017. Savanna Dry was introduced in 1996 and also comes in Light, Angry Lemon and Alc Free variants, excluding other limited run variants like Loco, Blackbeard and Neat. The Elgin Valley east of Cape Town grows around 60% of all the apples in South Africa. As a result, the region also has a vibrant craft cider scene, with brands like Sxollie, Everson's, Cluver & Jack, Windermere and Terra Madre all produced in the area. Sxollie Cider is increasingly being exported around the world, especially to the UK. Almost 90% of all the Sxollie produced is exported. Sxollie is pronounced like "skollie". Sxollie's Pink Lady Cider won Supreme Champion at the International Cider Challenge in 2019. Windermere Cider began brewing in 1994 and is regarded as the oldest craft cider brewery in South Africa. Loxtonia Cider, produced in the Ceres area, was crowned the overall champion at the 11th International Cider Challenge in London in 2021. Loxtonia's Alexandra Blush Méthode Traditionelle was named Supreme Champion for 2021 and won the Rosé Trophy as the best cider made in the rosé style.
Sources: en.wikipedia.org
=== Selection for Tavistock === In March 1965, Heseltine applied to be candidate for the safe Conservative seat of Tavistock in Devon, where the incumbent MP had announced his retirement two months earlier. Of the 51 applicants, 14 were considered, six of whom had local connections. Heseltine reached the final short list of three, the others being a dairy farmer in a senior position at the Milk Marketing Board (thought to be the favourite), and a local authority lawyer, who later recalled that on the train down from London Heseltine kept jumping out at every stop to check that his magazines were on display at the station newsagents. Heseltine had already spent several days driving round talking to locals and had ordered a year's worth of back copies of Tavistock's two weekly papers. Such effort is nowadays common in Parliamentary selections but was unusual at the time. He was selected by a clear majority of the Tavistock Conservative Association's Finance and General Purposes Committee (which contained between 100 and 120 people). Heseltine was picked in part as a young, dynamic candidate who could face the challenge of the resurgent Liberal Party in the West Country, where Jeremy Thorpe, Peter Bessell and Mark Bonham Carter had recently won seats. The Liberals had halved the Conservative majority at Tavistock in 1964. Trouble then arose at his adoption by a full general meeting of the Conservative Association, which should have been a formality.
=== Collection and purification === Due to its extreme lethality, as well as it being only commercially available at certain times and then at an extremely high cost, Amanita phalloides had to be retrieved from the wild in order to collect the β-Amanitin protein. This was first achieved by collecting A. phalloides fruiting bodies in New Jersey in 1975. These mushrooms were then dried for 24 hours and then ground in a blender with water. The slurry created was homogenized further to break open any intact cells, and after this a brown syrup extract containing the toxins was collected. This extract was then taken through various separation methods to isolate the toxins themselves. The toxins were then desalted and taken through four different methods of sephadex and acidic protein purification.
== Early life and education == Badu-Tawiah is from rural Ghana. He was one of three graduates of a high school class of 500 that went on to attend university. He earned his bachelor's and master's degree at the Kwame Nkrumah University of Science and Technology. In 2005 he moved to the United States, where he joined the laboratory of R. Graham Cooks at Purdue University to study high-performance liquid chromatography. There he studied reactions in mass spectrometers, and started to investigate whether this unique environment could be used for synthesis. Whilst at Purdue, Badu-Tawiah was awarded several research fellowships, including the Andrews and Lilly Innovation Fellowships. In 2012 Badu-Tawiah joined Harvard University where he worked in the research laboratory of George M. Whitesides. There he developed paper-based systems capable of performing molecular recognition. In particular, Badu-Tawiah looked to develop macrofluidic platforms that could analyse for specific biomarkers. Unfortunately, the enzymes required to detect biomarkers on paper-based platforms are not stable and require careful storage.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.